Supplemental Online Content


eFigure 1. Neutralizing capacity of SARS-CoV-2 spike protein antibodies
eFigure 2. SARS-CoV-2 spike protein specific interferon-gamma release assay results before and four weeks after the third vaccination
eFigure 3. Reactogenicity following third vaccination
eFigure 4. Interferon-gamma release assay results in healthy subjects after two doses of mRNA vaccine

This supplemental material has been provided by the authors to give readers additional information about their work.
Supplemental eFigure 1. Neutralizing capacity of SARS-CoV-2 spike protein antibodies. The functional neutralization capacity of the antibody response is plotted on the x-axis (a ≥30% signal inhibition in the surrogate virus neutralization test indicates the presence of neutralizing antibodies and is visualized by a horizontal line). SARS-CoV-2 specific antibody levels assessed by immunoassay are plotted on the y-axis (antibody levels >15 U/ml, >100 U/ml, >141 BAU/ml and >264 BAU/ml are visualized by vertical lines).
Supplemental eFigure 2. SARS-CoV-2 spike protein specific interferon-gamma release assay results before and four weeks after the third vaccination. Overall response was low but a statistically significant increase of patients interferon-gamma levels after the third vaccination was observed.
Supplemental eFigure 3. Reactogenicity following third vaccination. Severity of local and systemic side effects were graded by patients on a visual analogue scale (0: no symptoms, 1-2: mild, 3-4 moderate and 5 severe). There was no statistically significant difference between mRNA and vector group except for local pain at the injection side.
Supplemental eFigure 4. Interferon-gamma release assay results in healthy subjects after two doses of mRNA vaccine. All individuals had a response above 0.1 IU/ml (cut-off was calculated as mean plus two standard deviations in pre-pandemic control samples).